FRAGILE X SYNDROME NEWSLETTER | FXS Newsletter
FRAGILE X SYNDROME NEWSLETTER
Fragile X Syndrome, a syndrome, which results in intellectual disabilities as well
as affects the physical characteristics of the people suffering from it, is a
result of mutation associated with the gene known as FMR1.
As per DelveInsight assessments, the market size of Fragile
X Syndrome (FXS) in the 7MM was found to be USD 33.51 Million in 2017,
for the study period, 2017–2028.
Top
companies involved fuelling the FXS Market are:
Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics,
Confluence Pharmaceuticals, Neuren Pharmaceuticals, and others.
Through its Newsletter series, DelveInsight aims to brings to
light an overview of Fragile X syndrome, along with its epidemiological
scenario, treatment landscape and upcoming therapies in the pipeline that shall
drive the market forward.
Visit to gain access
to our Newsletter: https://www.delveinsight.com/whitepaper-newsletter/fragile-x-syndrome
Comments
Post a Comment